Log in

NASDAQ:GBTGlobal Blood Therapeutics Stock Price, Forecast & News

$70.33
-0.25 (-0.35 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$67.31
Now: $70.33
$70.99
50-Day Range
$62.55
MA: $67.11
$71.12
52-Week Range
$39.95
Now: $70.33
$87.54
Volume756,600 shs
Average Volume953,857 shs
Market Capitalization$4.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.89
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Read More
Global Blood Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GBT
CUSIPN/A
Phone650-741-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.11 million
Book Value$9.61 per share

Profitability

Net Income$-266,770,000.00

Miscellaneous

Employees171
Market Cap$4.29 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive GBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.

Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

How has Global Blood Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Global Blood Therapeutics' stock was trading at $54.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GBT shares have increased by 28.2% and is now trading at $70.33. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Global Blood Therapeutics?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 4 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Global Blood Therapeutics.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Global Blood Therapeutics.

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics Inc (NASDAQ:GBT) announced its earnings results on Wednesday, May, 6th. The company reported ($1.20) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.47) by $0.27. The company earned $14.12 million during the quarter, compared to analysts' expectations of $3.65 million. During the same period in the prior year, the business posted ($0.87) EPS. View Global Blood Therapeutics' earnings history.

What price target have analysts set for GBT?

19 analysts have issued 12 month target prices for Global Blood Therapeutics' stock. Their forecasts range from $60.00 to $150.00. On average, they expect Global Blood Therapeutics' share price to reach $103.56 in the next twelve months. This suggests a possible upside of 47.2% from the stock's current price. View analysts' price targets for Global Blood Therapeutics.

Has Global Blood Therapeutics been receiving favorable news coverage?

Headlines about GBT stock have trended positive on Wednesday, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Global Blood Therapeutics earned a coverage optimism score of 2.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Global Blood Therapeutics.

Are investors shorting Global Blood Therapeutics?

Global Blood Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 10,160,000 shares, an increase of 6.3% from the June 15th total of 9,560,000 shares. Based on an average trading volume of 873,900 shares, the days-to-cover ratio is currently 11.6 days. Approximately 17.1% of the shares of the company are short sold. View Global Blood Therapeutics' Current Options Chain.

Who are some of Global Blood Therapeutics' key competitors?

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Cynosure (CYNO), TherapeuticsMD (TXMD), Exelixis (EXEL), AbbVie (ABBV), Advanced Micro Devices (AMD), Square (SQ) and Vertex Pharmaceuticals (VRTX).

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the following people:
  • Dr. Ted W. Love, Pres, CEO & Director (Age 60)
  • Dr. Charles J. Homcy, Founder, Advisor & Director (Age 71)
  • Mr. Jeffrey S. Farrow, Chief Financial Officer (Age 57)
  • Mr. Peter Radovich, Sr. VP of Operations (Age 41)
  • Dr. Hing Sham, Sr. VP of Research (Age 67)

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $70.33.

How big of a company is Global Blood Therapeutics?

Global Blood Therapeutics has a market capitalization of $4.29 billion and generates $2.11 million in revenue each year. The company earns $-266,770,000.00 in net income (profit) each year or ($4.71) on an earnings per share basis. Global Blood Therapeutics employs 171 workers across the globe.

What is Global Blood Therapeutics' official website?

The official website for Global Blood Therapeutics is www.gbt.com.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 181 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.